ERYP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Jun 2023 @ 03:48):

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States...

Stats
今日成交量	3 205.00
平均成交量	148 586
市值	47.38M
EPS	$0 ( 2023-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-78.00
ATR14	$0.108 (13.85%)

音量相关性

長: 0.13 (neutral)

短: -0.16 (neutral)

Signal:(42.503) Neutral

Erytech Pharma S.A. 相关性

10 最正相关
DGHI	0.897
ITMR	0.884
AVEO	0.874
SOHON	0.868
CHDN	0.859
DVCR	0.851
SOHOB	0.848
XLO	0.847
BTBT	0.846
KIN	0.846

10 最负相关
AMRB	-0.873
SABS	-0.861
ORRF	-0.857
VTIP	-0.857
TRIB	-0.846
POLA	-0.837
SGMA	-0.833
SOPA	-0.816
MMAC	-0.814
LFMD	-0.809

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Erytech Pharma S.A. 相关性 - 货币/商品

-0.24
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.17
( neutral )

0.61
( weak )

0.11
( neutral )

Erytech Pharma S.A. 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.00740

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.00740

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.68

FY	2020
营收:	$0.00
毛利润:	$-57.58M (0.00 %)
EPS:	$-3.65

Financial Reports:

No articles found.

Erytech Pharma S.A.

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.